Well known Mover to Watch- Teva Pharmaceutical Industries Limited (NYSE:TEVA)

When it comes to the Analysis of a Stock, Price Target plays a vital role. The company now has an average rating of "Buy" and an average price target of $67.54. 11 analysts have rated the company as a strong "Hold". Citigroup maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rating on Tuesday, July 28. Teva Pharmaceutical Industries Limited P/E (price to earnings) ratio is 33.56 and Forward P/E ratio of 8.47. 22 Analysts reported that the Price Target for Teva Pharmaceutical Industries Limited might touch $100 high while the Average Price Target and Low price Target is $68.36 and $57 respectively. Finally, Jefferies Group set a $69.00 price target on Teva Pharmaceutical Industries and gave the stock a "buy" rating in a research report on Monday, September 12th. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and a consensus target price of $67.54.

On 9/26/2016, shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) fell -2.33% in trading session and finally closed at $50.27.

Another recent and important Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) news was published by Businessfinancenews.com which published an article titled: "Teva Pharmaceutical Industries Ltd (ADR), Allergan Near To Be One" on July 14, 2016. The stock has relative volume of 0.74. However, its previous closing price was seen at $51.47.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, August 4th.

While looking at the Stock's Performance, Teva Pharmaceutical Industries Limited now shows a Weekly Performance of -0.85%, where Monthly Performance is -1.82%, Quarterly performance is 4.25%, 6 Months performance is -7.31% and yearly performance percentage is -13.15%. The business's revenue for the quarter was up 1.4% on a year-over-year basis. The firm earned "Buy" rating on Tuesday, July 28 by Deutsche Bank.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Monday, August 22nd were issued a $0.34 dividend. The ex-dividend date of this dividend was Thursday, August 18th. It has a dividend yield of 2.71%. Renaissance Technologies LLC now owns 1,191,263 shares of the company's stock valued at $63,744,000 after buying an additional 658,763 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC increased its stake in shares of Teva Pharmaceutical Industries by 143.7% in the second quarter. Investec Asset Management LTD now owns 2,171,655 shares of the company's stock valued at $116,205,000 after buying an additional 1,148,997 shares during the last quarter. The Market Capitalization of the company stands at 50.43 Billion.

Shares of Rexahn Pharmaceuticals, Inc. TIAA CREF Investment Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 51.4% in the first quarter.

Thompson Siegel & Walmsley Llc, which manages about $7.40B and $6.11 billion US Long portfolio, decreased its stake in Gaming And Leisure Properties (NASDAQ:GLPI) by 130,975 shares to 1.16M shares, valued at $35.98M in 2016Q2, according to the filing. Renaissance Technologies LLC boosted its stake in shares of Teva Pharmaceutical Industries by 123.7% in the first quarter. The Company holds 1003.21 million shares outstanding.

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines.

  • Zachary Reyes